icon-folder.gif   Conference Reports for NATAP  
 
  HIV Drug Therapy Glasgow 2024
10-13 November
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety Analysis of Lenacapavir With Broadly Neutralising Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Highly Sensitive to One or Both Broadly Neutralising Antibodies
 
 
 

1114241

1114242

1114243

1114244

1114245

1114246

1114247

1114248